Business, energy, technology, markets and global industry news from Business News Today

radiopharmaceuticals

PharmaDeviceNews radiopharmaceuticals
Representative image of radiopharmaceutical preparation and PET imaging, illustrating how the Sanyou Bio and Baiyunshan Xihe collaboration aims to combine AI-led antibody discovery with nuclear medicine development for precision oncology.
Medical Devices & Diagnostics

AI meets nuclear medicine as Sanyou Bio and Baiyunshan Xihe pursue cancer diagnostics

Explore how Sanyou Bio and Baiyunshan Xihe are combining AI discovery and nuclear medicine to advance precision oncology theranostics.

Read More
Representative image: A nuclear medicine clinician monitors intravenous radiopharmaceutical administration, reflecting Radnostix’s acquisition of Lucerno Dynamics assets and its expansion into real-time extravasation monitoring, dosimetry and radioligand therapy workflows.
Medical Devices & Diagnostics

Lucerno Dynamics asset deal gives Radnostix new route into nuclear medicine workflows

Discover how Radnostix’s Lucerno Dynamics deal could reshape radiopharmaceutical monitoring, dosimetry and theranostics delivery.

Read More
Representative image: A PET/CT imaging suite illustrates how Pentixapharm’s [68Ga]Ga-PentixaFor Phase 3 PANDA study could reshape primary aldosteronism diagnostics and cardiovascular precision medicine.
Medical Devices & Diagnostics

Why a CXCR4 PET/CT tracer could become Pentixapharm’s most important cardiovascular asset

See why Pentixapharm’s Phase 3 CXCR4 PET/CT push could challenge a stubborn diagnostic bottleneck in primary aldosteronism.

Read More
Representative image of a clinician reviewing prostate cancer imaging in a modern nuclear medicine setting, reflecting Convergent Therapeutics’ CONV01-α Phase 2 data and the growing race to develop Actinium-225 radiopharmaceuticals for post-Lu-PSMA metastatic prostate cancer.
Pharma & Biotech

Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?

CONV01-α is targeting the post-Lu-PSMA prostate cancer gap. Convergent now faces the Phase 3 test that will decide its real value.

Read More
Representative image: Actinium Pharmaceuticals’ ATNM-400 update and new Actimab-A and Iomab-ACT patent allowances underscore rising investor and clinical interest in targeted radiotherapy, actinium-225 cancer treatments and next-generation radiopharmaceuticals.
Pharma & Biotech

Actinium’s radiotherapy push gains IP depth as ATNM-400 heads to SNMMI 2026

Actinium’s science story is widening, but its balance sheet pressure is now impossible to ignore. ATNM-400 data may decide the next chapter.

Read More
Representative image of radioligand therapy research for cancer-associated bone disease, highlighting how LIFT and NorthStar’s Lu-177-LT17 collaboration could advance targeted oncology treatment for bone lesions.
Pharma & Biotech

Can LIFT and NorthStar move Lu-177-LT17 into the next radioligand therapy frontier?

Find out how LIFT and NorthStar’s Lu-177-LT17 partnership could advance radioligand therapy for cancer bone disease today!

Read More
Representative image: A sterile radiopharmaceutical manufacturing cleanroom with shielded processing equipment and sealed vials, illustrating how Niowave’s Michigan Actinium-225 facility could support the next phase of targeted cancer therapy supply.
Pharma & Biotech

Can Niowave’s Michigan facility ease the Actinium-225 bottleneck in cancer therapy?

Find out how Niowave’s $75m Michigan facility could reshape Actinium-225 supply for targeted cancer therapies.

Read More
Pharma & Biotech

How Full-Life Technologies is using US$150m to push beyond platform promise

Radiopharma needs more than promising targets. Full-Life’s US$150m raise puts actinium-225 supply and clinical execution in focus.

Read More
Representative image: Telix Pharmaceuticals’ PSMA-PET imaging collaborations with EDAP TMS and Profound Medical highlight how advanced prostate cancer scans could support minimally invasive treatment planning, focal ablation decisions and post-treatment monitoring in next-generation urology workflows.
Medical Devices & Diagnostics

Why Telix is taking PSMA-PET deeper into minimally invasive prostate cancer treatment

Prostate ablation is getting more precise. Telix wants PSMA-PET to become the imaging layer that helps clinicians decide where to treat.

Read More
Representative image: A modern radioligand therapy manufacturing centre under construction in Texas, highlighting Novartis AG’s investment in U.S. oncology infrastructure and the growing race to scale precision cancer treatment supply chains.
Medical Devices & Diagnostics

Novartis bets on Texas as radioligand therapy moves closer to mainstream oncology

RLT demand is rising faster than supply chains can stretch. Novartis’ Texas buildout tests whether precision oncology can scale.

Read More